Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
IPO Year: 2019
Exchange: NYSE
Website: alcon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/12/2024 | Buy | Needham | |
| 10/10/2024 | Sell → Neutral | Redburn Atlantic | |
| 9/10/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 7/15/2024 | $65.00 → $85.00 | Underweight → Equal-Weight | Morgan Stanley |
| 5/15/2024 | $103.00 | Perform → Outperform | Oppenheimer |
| 4/10/2024 | $100.00 | Buy | Goldman |
| 3/14/2024 | Sector Perform | RBC Capital Mkts | |
| 2/6/2024 | $87.00 | Overweight | KeyBanc Capital Markets |
| 1/23/2024 | $94.40 | Outperform | Bernstein |
| 12/18/2023 | Neutral → Sell | Redburn Atlantic |
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for comfort and affordability when a daily disposable lens is not an option1,3* Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 Wh
Attendees can experience a first look at Voyager DSLT, Alcon's new first-line laser therapy for glaucoma patients Alcon introduces new handheld gas delivery systems, UNIFEYE and UNIPEXY, optimizing convenience and accuracy for retina surgeons In addition, Alcon presents pivotal data for AR-15512 (acoltremon 0.003%)*, a prescription drug candidate undergoing FDA review for the treatment of dry eye Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior to broad commercialization in 2025 First innovations to be introduced from Alcon's cutting-edge Unity portfolio of surgical equipment Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Admi
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta
Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of
Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters Proposed dividend of CHF 0.24 cash per share Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to t
Vivity is the most implanted extended depth of focus (EDOF) intraocular lens (IOL) globally1 Vivity is the first and only wavefront-shaping IOL with Alcon's proprietary X-WAVE Technology2-3 Vivity demonstrates excellent outcomes, with real-world Vivity Registry data from more than 900 cataract patients, including patients with certain mild comorbidities4 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the gl
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17. Earnings Estimates: Analysts expect Johnson & Johnson to report second-quarter revenue of $22.31 billion, according to data from Benzinga Pro. The company reported revenue of $25.53 billion in last year's second quarter, meaning analysts see a revenue decline on a year-over-year basis. Johnson & Johnson has beaten revenue estimates in six of the past 10 quarters and four of the last five quarters.
BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $92 to $96.
Morgan Stanley analyst Patrick Wood upgrades Alcon (NYSE:ALC) from Underweight to Equal-Weight and raises the price target from $65 to $85.
Needham analyst David Saxon reiterates Alcon (NYSE:ALC) with a Buy and maintains $101 price target.
Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon's highly anticipated Unity portfolio. "At Alcon, we have a long legacy of involving our customers throughout the research and development process to deliver bold innovation in ophthalmology, and we would like to thank those who helped us arrive at today's milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We are excited to introduce th
These large-cap stocks were the best performers in the last week. Are they in your portfolio? MicroStrategy Incorporated (NASDAQ:MSTR) shares increased 30.10% following a rise in the price of Bitcoin. Monday.Com (NASDAQ:MNDY) shares jumped 25.97% following better-than-expected Q1 financial results and a Q2 FY24 revenue guidance above estimates. Several analysts boosted price targets for the company. On Holding AG (NYSE:ONON) shares soared 15.02% after it reported better-than-expected financial results, and analysts raised the price target on the stock. Sea Limited (NYSE:SE) shares rose 13.99% following a Q1 revenue beat, and Tiger Global increased its stake in the company. In
Oppenheimer has upgraded Alcon Inc (NYSE:ALC) following firm first-quarter earnings and several new drivers coming into view. The analyst sees a new opportunity in glaucoma with the announced acquisition of BELKIN Vision for $60 million immediately and up to $335 million with milestone payments. Via the BELKIN Vision deal, Alcon adds FDA-approved Eagle direct-SLT for glaucoma. Selective Laser Trabeculoplasty (SLT) stimulates the trabecular meshwork to increase fluid drainage/lower Intraocular pressure (IOP). The analyst also writes that Eagle has differentiating characteristics including shorter treatment time. Once closed, BELKIN will broaden ALC’s reach into glaucoma treatment.
Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:ALC) with a Overweight and raises the price target from $89 to $94.
Oppenheimer analyst Steven Lichtman upgrades Alcon (NYSE:ALC) from Perform to Outperform and announces $103 price target.
Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $100 to $105.
Needham reiterated coverage of Alcon with a rating of Buy
Redburn Atlantic upgraded Alcon from Sell to Neutral
RBC Capital Mkts upgraded Alcon from Sector Perform to Outperform
Morgan Stanley upgraded Alcon from Underweight to Equal-Weight and set a new price target of $85.00 from $65.00 previously
Oppenheimer upgraded Alcon from Perform to Outperform and set a new price target of $103.00
Goldman initiated coverage of Alcon with a rating of Buy and set a new price target of $100.00
RBC Capital Mkts initiated coverage of Alcon with a rating of Sector Perform
KeyBanc Capital Markets resumed coverage of Alcon with a rating of Overweight and set a new price target of $87.00
Bernstein initiated coverage of Alcon with a rating of Outperform and set a new price target of $94.40
Redburn Atlantic downgraded Alcon from Neutral to Sell
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
SD - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
SD - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta
Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of
Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters Proposed dividend of CHF 0.24 cash per share Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to t
Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency(1) (cc) Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year(3); core diluted EPS(2) of $0.70 up 67%, or 78% cc FY 2023 sales of $9.4 billion, up 8%, or 10% cc FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33% cc FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and
Third quarter 2023 sales of $2.3 billion, up 8%, or 9% constant currency(1) (cc) Third quarter 2023 diluted EPS of $0.41, up 78%, or up 97% cc; core diluted EPS(2) of $0.66 up 32%, or 41% cc Generated $937 million of cash from operating activities and $592 million of free cash flow(3) in the first nine months of 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023. For the third quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 9% on a constant currency basis(1), as compared to the same quarter of the previous year.
Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency(1) (cc) Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS(2) of $0.69 up 10%, or 19% cc Based on strong operational performance and improved outlook, Company raises full year 2023 sales and core diluted EPS guidance Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and six months ended June 30, 2023. For the second quarter of 2023, sales were $2.4 billion, an increase of 9% on a reported basis and 12% on a constant currency basis(1), as compared to the same quarter of the previous year.
First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency(1) (cc) First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS(2) of $0.70 up 3%, or 14% cc Dividend of CHF 0.21 per share approved by shareholders at the Annual General Meeting on May 5, 2023 Raised full year 2023 cc sales and core diluted EPS growth outlook Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2023. For the first quarter of 2023, sales were $2.3 billion, an increase of 7% on a reported basis and 11% on a constant currency basis(1), as compared to the same
Shareholders approve dividend of CHF 0.21 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation Report in an advisory vote, as well as the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM). A total of 321,168,907 shares with